Abstract
The role of angiogenesis in haematological malignancies has been recently recognized. In these tumors, angiogenesis has been investigated predominantly in the bone marrow (BM) compartment where it appears to be regulated by multiple interactions between malignant cells and different cell populations present in the tumor microenvironment. Thus, angiogenesis represents a therapeutic target that opens new perspectives for the treatment of haematological malignancies. Cytokines are small proteins that mediate intercellular communications, thus regulating important cellular functions, such as immune responses and angiogenesis. Some cytokines show anti-angiogenic properties through different mechanisms; these cytokines can interfere directly with biological functions of endothelial cells and/or target tumor cells inhibiting their capability to stimulate formation of new microvessels that are essential for tumor growth and dissemination. In this review we will summarize the current knowledge about the role of cytokines as anti-angiogenic agents in cancer, focusing our attention on the anti-angiogenic activity of IL-12 family members in haematological malignancies.
Keywords: Angiogenesis, cytokines, cytokine receptors, haematological malignancies, acute myeloid leukemia, angiopoietin, B cell acute ymphoblastic leukemia, B cell chronic lymphocytic leukemia, bone marrow, chorioallantoid membrane, fibroblast growth factor, granulocyte colony stimulating factors, interferon, interleukin
Current Cancer Drug Targets
Title: Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Volume: 11 Issue: 9
Author(s): C. Cocco, E. Ferretti, I. Airoldi and V. Pistoia
Affiliation:
Keywords: Angiogenesis, cytokines, cytokine receptors, haematological malignancies, acute myeloid leukemia, angiopoietin, B cell acute ymphoblastic leukemia, B cell chronic lymphocytic leukemia, bone marrow, chorioallantoid membrane, fibroblast growth factor, granulocyte colony stimulating factors, interferon, interleukin
Abstract: The role of angiogenesis in haematological malignancies has been recently recognized. In these tumors, angiogenesis has been investigated predominantly in the bone marrow (BM) compartment where it appears to be regulated by multiple interactions between malignant cells and different cell populations present in the tumor microenvironment. Thus, angiogenesis represents a therapeutic target that opens new perspectives for the treatment of haematological malignancies. Cytokines are small proteins that mediate intercellular communications, thus regulating important cellular functions, such as immune responses and angiogenesis. Some cytokines show anti-angiogenic properties through different mechanisms; these cytokines can interfere directly with biological functions of endothelial cells and/or target tumor cells inhibiting their capability to stimulate formation of new microvessels that are essential for tumor growth and dissemination. In this review we will summarize the current knowledge about the role of cytokines as anti-angiogenic agents in cancer, focusing our attention on the anti-angiogenic activity of IL-12 family members in haematological malignancies.
Export Options
About this article
Cite this article as:
Cocco C., Ferretti E., Airoldi I. and Pistoia V., Cytokines as Anti-Angiogenic Agents in Haematological Malignancies, Current Cancer Drug Targets 2011; 11 (9) . https://dx.doi.org/10.2174/156800911798073096
DOI https://dx.doi.org/10.2174/156800911798073096 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemistry of Plant Dyes: Applications and Environmental Implications of Dyeing Processes
Current Environmental Engineering Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Current Concepts of Immunopathogenesis, Diagnosis and Therapy in Whipples Disease
Current Medicinal Chemistry ENaC Modulators and Renal Disease
Current Molecular Pharmacology Diquaternized Curarelike Myorelaxants: Structure and Biological Activity
Mini-Reviews in Medicinal Chemistry Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-dipping Status in Arterial Hypertension: An Overview
Current Vascular Pharmacology A Novel Therapeutic Strategy Against Vascular Disorders with Chymase Inhibitor
Current Vascular Pharmacology Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) Evolution of Biomarker Guided Therapy for Heart Failure: Current Concepts and Trial Evidence
Current Cardiology Reviews Diagnostic Cardiac Catheterization in the Pediatric Population
Current Cardiology Reviews Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Anti-Cancer Agents in Medicinal Chemistry Research Advances in Neuroblastoma Immunotherapy
Current Pediatric Reviews Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies
Current Pharmaceutical Design The Impact of Methodology and Confounding Variables on the Association Between Major Depression and Coronary Heart Disease: Review and Recommendations
Current Psychiatry Reviews Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design